Enigma gains PCR patents:
This article was originally published in Clinica
Enigma Diagnostics has gained 25 patents and patent applications from the UK's Defence Science and Technology Laboratory (Dstl) after signing an exclusive licensing deal. The patents relate to a broad range of real-time PCR technologies in development, including Pyrostart, ResonSense and Temperature Control. The PCR systems are being developed for the real-time detection and identification of infectious organisms in clinical, environmental and biological samples. Under the agreement, Porton Down, UK-based Enigma will be able to develop its own patent portfolio with any improvement that is made to the technologies. It will also enable the company to sub-license the technologies for PCR and non-PCR applications. The patents, which were previously the responsibility of Dstl, are managed by Enigma with effect from August 13. The licence agreement will remain in place until 2026.